Stockreport

Aeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)

Aeglea BioTherapeutics, Inc.  (AGLE) 
Last aeglea biotherapeutics, inc. earnings: 8/6 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.aegleabio.com/investor-overview
PDF AUSTIN, Texas, April 08, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human e [Read more]